Now Playing
|Videos|June 19, 2023
Demographics and Pathogenesis of Plaque Psoriasis
Brad Glick, MD; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, provide an overview of plaque psoriasis, highlighting demographics and risk factors, as well as the pathophysiology of the disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Bepirovirsen for Chronic Hepatitis B
2
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
3
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
4
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
5